Florian Lordick, Oncologist, Professor of Medicine at University of Leipzig, Head of Medical Oncology, Director of the Comprehensive Cancer Center Central, Germany, shared on LinkedIn:
“New publication in ESMO Gastrointestinal Oncology
Pleased to share our new Mini Review on the evolving role of adjuvant treatment in gastrointestinal stromal tumors (GIST), together with Anne-Marie Scheuble from Leipzig University, Universitätsklinikum Leipzig AöR Leipzig and Robert G., Maki Memorial Sloan Kettering Cancer Center.
The field is moving beyond a ‘one-size-fits-all’ approach. We discuss:
Who truly benefits from 3 years of adjuvant imatinib – and who may need longer treatment.
The growing importance of KIT and PDGFRA mutational profiling for personalized decision-making.
Current controversies around intermediate-risk disease and tumor rupture. Future perspectives using multiomics and AI-based risk stratification to better identify patients who will benefit from adjuvant therapy while avoiding overtreatment.
A practical overview of where we stand today—and where personalized GIST management is heading.”
Title: Adjuvant treatment of gastrointestinal stromal tumors (GIST) – state of the art, controversies, and future directions
Authors: A.-M. Scheuble, F. Lordick, R.G. Maki
Read the Full Article
Other articles about Gastrointestinal Oncology on OncoDaily.